Skip to main content

Table 1 Baseline characteristics of patients

From: A retrospective study of the clinical benefit from acetylsalicylic acid desensitization in patients with nasal polyposis and asthma

Age-year, mean (range)

50.7 (17–75)

  Male, n (%)

58 (52.2)

  Female, n (%)

53 (47.8%)

Length of upper respiratory disease (%)

  <5 years

22.2

  5-10 years

28.3

  10-15 years

15.2

  >15 years

34.3

Length of lower respiratory disease (%)

  <5 years

33.7

  5-10 years

25.3

  10-15 years

10.8

  >15 years

30.2

Baseline FEV1 (n)

Post ASA FEV1 (n)

  Mild (≥80)

25

32

  Moderate (<80 × ≥50)

36

36

  Severe (<50)

2

2

  Unknown

48

41